CDBRM Labs

Bennett Lab

The Bennett lab investigates the contribution of post-zygotic mutations on human development and birth defects, with a focus on vascular malformations. We also study the impact of rapid diagnostic genomic sequencing in management of children in intensive care units.

The impact of somatic mutation on birth defects

Almost all genetic sequencing in children is performed from blood derived DNA, which implicitly assumes that the genomes of blood cells are the same as every other cell in the body. Because errors occur in DNA replication with every division, and an enormous amount of cell division occurs during human development, we know that all children are born with genetic variants that are not present in every cell in the body. This has major implications for diagnosis of children with genetic disorders, since pathogenic mutations that are absent, or present at low levels in the blood will not be detected by current standard methods.

To address this, the Bennett lab is developing methods for accurate detection of these low-level mosaic variants. We are measuring the baseline rate of post zygotic mutation during human development, with a goal of defining the global tissue distribution of somatic mutations present in a newborn infant.

Precision medicine for vascular malformations

Vascular malformations are a heterogeneous and common group of disorders characterized by abnormal development of arteries, capillaries, veins, and lymphatic vessels. The vast majority of patients with vascular malformations have no family history, and historically these malformations have been classified based on imaging and histopathological features.

Recently many of these “sporadic” vascular malformations have been recognized as being due to post-zygotic mutations. In collaboration with Dr. Jonathan Perkins, director of the Vascular Anomalies Program, the Bennett lab is working to identify disease-causing mutations in a large cohort of patients with vascular malformations. In addition to discovering novel genes, we are correlating genetic causes with detailed clinical information, which can be used to provide additional prognostic information for individuals with these conditions, and will lead to novel therapies.

Rapid genomic sequencing in the inpatient hospital setting

Exome and genome sequencing has revolutionized molecular diagnosis of children with rare genetic disease. A large number of publications have already shown that 25-50% of children with congenital malformations and/or genetic encephalopathies will be diagnosed by exome or genome sequencing. However, the impact of these specific molecular diagnoses on inpatient management has not been demonstrated. A major hurdle for testing in this setting has been the traditionally slow turnaround time (4-6 weeks or longer) for genetic testing. This is usually too slow to impact major decision making in the inpatient setting.

Taking advantage of the availability of clinical exome sequencing with rapid (~1 week) turnaround times, the Bennett lab is leading a project within Seattle Children’s Hospital (the Rapid Inpatient Genomic Testing, or “RIGhT” project), which is measuring the impact of this kind of testing in critically ill patients via retrospective chart review. Our hypothesis is that rapid molecular diagnosis leads to improved decision making in the ICU. This project is a collaborative effort with faculty of the Division of Genetic Medicine and the Department of Lab Medicine.

Remote Access

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.